Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy

Antioxidants and Redox Signaling

Volumn 15, Issue 8, 2011, Pages 2095-2107

  Galino, Jorge ^a,b   Ruiz, Montserrat ^a,b   Fourcade, Stéphane ^a,b   Schlüter, Agatha ^a,b   López Erauskin, Jone ^a,b   Guilera, Cristina ^a,b   Jove, Mariona ^c   Naudi, Alba ^c   García Arumí, Elena ^b,d   Andreu, Antoni L ^b,d   Starkov, Anatoly A ^e   Pamplona, Reinald ^c   Ferrer, Isidre ^a,b   Portero Otin, Manuel ^c   Pujol, Aurora ^a,b,f  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF LLEIDA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e WEILL CORNELL MEDICAL CENTER   (United States)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ACETYLCYSTEINE; ACONITATE HYDRATASE; ADENOSINE TRIPHOSPHATE; ATP BINDING CASSETTE PEROXISOMAL TRANSPORTER D1; CITRATE SYNTHASE; DIHYDROLIPOAMIDE DEHYDROGENASE; FRUCTOSE BISPHOSPHATE ALDOLASE; FUMARATE HYDRATASE; GLUTATHIONE; GLYCOLYTIC ENZYME; LACTATE DEHYDROGENASE; MALATE DEHYDROGENASE; PHOSPHOGLYCERATE KINASE; PYRUVATE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THIOCTIC ACID; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID;

ADRENOLEUKODYSTROPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CITRIC ACID CYCLE; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVITY; FIBROBLAST; HUMAN; LIPID DEGRADATION; MOTOR DYSFUNCTION; MOUSE; NERVE FIBER DEGENERATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEOMICS; SPINAL CORD ATROPHY;

ADENOSINE TRIPHOSPHATE; ADRENOLEUKODYSTROPHY; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENERGY METABOLISM; GLUTATHIONE; HUMANS; MALE; MICE; MICE, INBRED C57BL; NAD; OXIDATIVE STRESS; PROTEOMICS; PYRUVATE KINASE;

MUS;

EID: 80052595429     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2010.3877     Document Type: Article

References (70)

1. Aliev G, Liu J, Shenk JC, Fischbach K, Pacheco GJ, Chen SG, Obrenovich ME, Ward WF, Richardson AG, Smith MA, Gasimov E, Perry G, and Ames BN. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J Cell Mol Med 13: 320-333, 2009.
2. Ambrus A, Tretter L, and Adam-Vizi V. Inhibition of the alpha-ketoglutarate dehydrogenase-mediated reactive oxygen species generation by lipoic acid. J Neurochem 109 Suppl 1: 222-229, 2009.
3. Arivazhagan P and Panneerselvam C. Effect of DLalpha-lipoic acid on neural antioxidants in aged rats. Pharmacol Res 42: 219-222, 2000.
4. Bagh MB, Thakurta IG, Biswas M, Behera P, and Chakrabarti S. Age-related oxidative decline of mitochondrial functions in rat brain is prevented by long term oral antioxidant supplementation. Biogerontology 12: 119-131, 2011.
5. Baumgart E, Vanhorebeek I, Grabenbauer M, Borgers M, Declercq PE, Fahimi HD, and Baes M. Mitochondrial alterations caused by defective peroxisomal biogenesis in a mouse model for Zellweger syndrome (PEX5 knockout mouse). Am J Pathol 159: 1477-1494, 2001. (Pubitemid 32947977)
6. Bisaglia M, Soriano ME, Arduini I, Mammi S, and Bubacco L. Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim Biophys Acta 1802: 699-706, 2010.
7. Browne SE, Yang L, DiMauro JP, Fuller SW, Licata SC, and Beal MF. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol Dis 22: 599-610, 2006. (Pubitemid 43832131)
8. Bulteau AL, Ikeda-Saito M, and Szweda LI. Redoxdependent modulation of aconitase activity in intact mitochondria. Biochemistry 42: 14846-14855, 2003. (Pubitemid 37553513)
9. Butterfield DA and Lange ML. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem 111: 915-933, 2009.
10. Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, and Markesbery WR. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 22: 223-232, 2006.
11. Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, and Mattson MP. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal 13: 1763-1811, 2010.
12. Calabrese V, Cornelius C, Maiolino L, Luca M, Chiaramonte R, Toscano MA, and Serra A. Oxidative stress, redox homeostasis and cellular stress response in Meniere's disease: role of vitagenes. Neurochem Res 35: 2208-2217, 2010.
13. Chan A, Paskavitz J, Remington R, Rasmussen S, and Shea TB. Efficacy of a vitamin/nutriceutical formulation for earlystage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am J Alzheimers Dis Other Demen 23: 571-585, 2008.
14. Di Domenico F, Perluigi M, Butterfield DA, Cornelius C, and Calabrese V. Oxidative damage in rat brain during aging: interplay between energy and metabolic key target proteins. Neurochem Res 35: 2184-2192, 2010.
15. Dodd S, Dean O, Copolov DL, Malhi GS, and Berk M. Nacetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 8: 1955-1962, 2008.
16. Ferrer I. Altered mitochondria, energy metabolism, voltagedependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. J Bioenerg Biomembr 41: 425-431, 2009.
17. Ferrer I, Aubourg P, and Pujol A. General aspects and neuropathology of X-linked adrenoleukodystrophy. Brain Pathol 20: 817-830, 2010.
18. Ferrer I, Kapfhammer JP, Hindelang C, Kemp S, Troffer-Charlier N, Broccoli V, Callyzot N, Mooyer P, Selhorst J, Vreken P,Wanders RJ,Mandel JL, and Pujol A. Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to lateonset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. Hum Mol Genet 14: 3565-3577, 2005. (Pubitemid 41754658)
19. Formentini L, Martinez-Reyes I, and Cuezva JM. The mitochondrial bioenergetic capacity of carcinomas. IUBMB Life 62: 554-560, 2010.
20. Fourcade S, Lopez-Erauskin J, Galino J, Duval C, Naudi A, Jove M, Kemp S, Villarroya F, Ferrer I, Pamplona R, Portero-Otin M, and Pujol A. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet 17: 1762-1773, 2008. (Pubitemid 351791502)
21. Fourcade S, Ruiz M, Camps C, Schluter A, Houten SM, Mooyer PA, Pampols T, Dacremont G, Wanders RJ, Giros M, and Pujol A. A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am J Physiol Endocrinol Metab 296: E211-E221, 2009.
22. Fourcade S, Ruiz M, Guilera C, Hahnen E, Brichta L, Naudi A, Portero-Otin M, Dacremont G, Cartier N, Wanders R, Kemp S, Mandel JL, Wirth B, Pamplona R, Aubourg P, and Pujol A. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet 19: 2005-2014, 2010.
23. Gibson GE, Starkov A, Blass JP, Ratan RR, and Beal MF. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim Biophys Acta 1802: 122-134, 2010.
24. Gilg AG, Singh AK, and Singh I. Inducible nitric oxide synthase in the central nervous system of patients with Xadrenoleukodystrophy. J Neuropathol Exp Neurol 59: 1063-1069, 2000. (Pubitemid 32006309)
25. Gispert S, Ricciardi F, Kurz A, AzizovM, HoepkenHH, Becker D, Voos W, Leuner K, Muller WE, Kudin AP, Kunz WS, Zimmermann A, Roeper J, Wenzel D, Jendrach M, Garcia-ArencibiaM, Fernandez-Ruiz J,Huber L, Rohrer H, BarreraM, Reichert AS, Rub U, Chen A, Nussbaum RL, and Auburger G. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 4: e5777, 2009.
26. Gutmann I and Bernt E. Methods of Enzymatic Analysis. New-York: Verlag Chemie Weinheim, Academic Press, Inc., 1974, pp. 774-777.
27. Hamm-Kunzelmann B, Schafer D, Weigert C, and Brand K. Redox-regulated expression of glycolytic enzymes in resting and proliferating rat thymocytes. FEBS Lett 403: 87-90, 1997. (Pubitemid 27079815)
28. Harvey BH, Joubert C, du Preez JL, and Berk M. Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. Neurochem Res 33: 508-517, 2008. (Pubitemid 351230453)
29. Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A, and Muller WE. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30: 1574-1586, 2009.
30. Herrero-Mendez A, Almeida A, Fernandez E, Maestre C, Moncada S, and Bolanos JP. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol 11: 747-752, 2009.
31. Hirrlinger J and Dringen R. The cytosolic redox state of astrocytes: maintenance, regulation and functional implications for metabolite trafficking. Brain Res Rev 63: 177-188, 2010.
32. Humphries KM and Szweda LI. Selective inactivation of alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2-nonenal. Biochemistry 37: 15835-15841, 1998. (Pubitemid 28524755)
33. Janero DR, Burghardt C, and Feldman D. Amphiphileinduced heart muscle-cell (myocyte) injury: effects of intracellular fatty acid overload. J Cell Physiol 137: 1-13, 1988.
34. Khan HA. Bioluminometric assay of ATP in mouse brain: determinant factors for enhanced test sensitivity. J Biosci 28: 379-382, 2003. (Pubitemid 36750045)
35. Lacraz G, Figeac F, Movassat J, Kassis N, Coulaud J, Galinier A, Leloup C, Bailbe D, Homo-Delarche F, and Portha B. Diabetic beta-cells can achieve self-protection against oxidative stress through an adaptive up-regulation of their antioxidant defenses. PLoS One 4: e6500, 2009.
36. Leuner K, Hauptmann S, Abdel-Kader R, Scherping I, Keil U, Strosznajder JB, Eckert A, and Muller WE. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid Redox Signal 9: 1659-1675, 2007. (Pubitemid 47462969)
37. Lin MT and Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795, 2006. (Pubitemid 44622683)
38. López-Erauskin J, Fourcade S, Galino J, Ruiz M, Schlü ter A, Naudi A, Jove M, Portero-Otin M, Pamplona R, Ferrer I, and Pujol A. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. Ann Neurol (in press); DOI: 10.1002/ana.22363, 2011.
39. Lu JF, Lawler AM,Watkins PA, Powers JM, Moser AB,Moser HW, and Smith KD. A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci USA 94: 9366-9371, 1997. (Pubitemid 27357835)
40. Martinez A, Portero-Otin M, Pamplona R, and Ferrer I. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol 20: 281-297, 2010.
41. Moreira PI, Harris PL, Zhu X, Santos MS, Oliveira CR, Smith MA, and Perry G. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis 12: 195-206, 2007. (Pubitemid 47509369)
42. Moser H, Smith KD, Watkins PA, Powers J, and Moser AB. X-linked adrenoleukodystrophy. In: The Metabolic and Molecular Bases of Inherited disease, edited by Scriver C. New-York: McGraw-Hill, 2001, pp. 3257-3301.
43. Nulton-Persson AC and Szweda LI. Modulation of mitochondrial function by hydrogen peroxide. J Biol Chem 276: 23357-23361, 2001.
44. Packer L, Tritschler HJ, and Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 22: 359-378, 1997.
45. Pamplona R and Barja G. Highly resistant macromolecular components and low rate of generation of endogenous damage: two key traits of longevity.Ageing ResRev 6: 189-210, 2007. (Pubitemid 47405306)
46. Parihar MS and Brewer GJ. Mitoenergetic failure in Alzheimer disease. Am J Physiol Cell Physiol 292: C8-C23, 2007. (Pubitemid 46115117)
47. Perluigi M, Di Domenico F, Giorgi A, Schinina ME, Coccia R, Cini C, Bellia F, Cambria MT, Cornelius C, Butterfield DA, and Calabrese V. Redox proteomics in aging rat brain: involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process. J Neurosci Res 88: 3498-3507, 2010.
48. Phillips SA and Thornalley PJ. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 212: 101-105, 1993. (Pubitemid 23064605)
49. Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, Callizot N, Ruiz M, Pampols T, Giros M, and Mandel JL. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet 13: 2997-3006, 2004. (Pubitemid 39585232)
50. Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, and Mandel JL. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet 11: 499-505, 2002. (Pubitemid 34257486)
51. Remington R, Chan A, Paskavitz J, and Shea TB. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. Am J Alzheimers Dis Other Demen 24: 27-33, 2009.
52. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Drose S, Brandt U, Savaskan E, Czech C, Gotz J, and Eckert A. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 106: 20057-20062, 2009.
53. Rinholm JE, Hamilton NB, Kessaris N, Richardson WD, Bergersen LH, and Attwell D. Regulation of oligodendrocyte development and myelination by glucose and lactate. J Neurosci 31: 538-548, 2011.
54. Robinson CE, Keshavarzian A, Pasco DS, Frommel TO, Winship DH, and Holmes EW. Determination of protein carbonyl groups by immunoblotting. Anal Biochem 266: 48-57, 1999. (Pubitemid 29024607)
55. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, and Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 35: 235-242, 2007.
56. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 32: 307-326, 2000. (Pubitemid 32001909)
57. Shenk JC, Liu J, Fischbach K, Xu K, Puchowicz M, Obrenovich ME, Gasimov E, Alvarez LM, Ames BN, Lamanna JC, and Aliev G. The effect of acetyl-L-carnitine and R-alphalipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J Neurol Sci 283: 199-206, 2009.
58. Singh I and Pujol A. Pathomechanisms underlying Xadrenoleukodystrophy: a three-hit hypothesis. Brain Pathol 20: 838-844, 2010.
59. Sowell RA, Owen JB, and Butterfield DA. Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Res Rev 8: 1-17, 2009.
60. Starkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, and Beal MF. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci 24: 7779-7788, 2004. (Pubitemid 39215681)
61. Stern N, Hochman A, Zemach N, Weizman N, Hammel I, Shiloh Y, Rotman G, and Barzilai A. Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains ofAtm-deficientmice. J BiolChem277: 602-608, 2002. (Pubitemid 34952097)
62. Tan JS, Wang JJ, Flood V, Rochtchina E, Smith W, and Mitchell P. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 115: 334-341, 2008. (Pubitemid 351175680)
63. Tarnopolsky MA. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv Drug Deliv Rev 60: 1561-1567, 2008.
64. Tretter L and Adam-Vizi V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J Neurosci 20: 8972-8979, 2000. (Pubitemid 32042897)
65. Tretter L and Adam-Vizi V. Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. Philos Trans R Soc Lond B Biol Sci 360: 2335-2345, 2005. (Pubitemid 46682153)
66. van RoermundCW,VisserWF, Ijlst L, van CruchtenA, BoekM, Kulik W, Waterham HR, and Wanders RJ. The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. FASEB J 22: 4201-4208, 2008.
67. Wikoff WR, Pendyala G, Siuzdak G, and Fox HS. Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J Clin Invest 118: 2661-2669, 2008. (Pubitemid 351949793)
68. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, and Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 106: 14670-14675, 2009.
69. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 10: 179-206, 2008.
70. Zhao Y, Seefeldt T, Chen W, Wang X, Matthees D, Hu Y, and Guan X. Effects of glutathione reductase inhibition on cellular thiol redox state and related systems. Arch Biochem Biophys 485: 56-62, 2009